Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

    Date Summary View
    Toggle Summary RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease
    The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US study   To date, over 300 of the planned 410 subjects, have been randomized in the ...
    View HTML
    Toggle Summary RedHill Biopharma Reports 2017 Second Quarter Financial Results
    RedHill maintains a debt-free balance sheet with $51 million cash 1  at the end of the second quarter of 2017  Select recent milestones include: Initial net revenues of approximately $0.5 million between June 12-30 following commencement of promotional activities in the U.S. ...
    View HTML
    Toggle Summary RedHill Biopharma to Host Second Quarter 2017 Financial Results Conference Call on July 25, 2017
    TEL-AVIV, Israel and RALEIGH, N.C. , July 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D
    Top-line results are expected in September 2017 The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA ®  (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D),   with a primary endpoint of ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease
    The second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn's disease (MAP US study) is planned to be held in late July 2017 and will assess the safety and efficacy of RHB-104 in the first 222 subjects who have completed week 26 assessments The ...
    View HTML
    Toggle Summary RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis
    TEL-AVIV, Israel and RALEIGH, N.C. , June 19, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA™) for H. pylori Infection
    Subject to a successful outcome and any additional regulatory feedback, the confirmatory Phase III study (ERADICATE Hp 2) is expected to complete the package required for a potential U.S. NDA for RHB-105, newly branded as TALICIA ™   The two-arm, randomized, double-blind, active comparator, ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis
    The positive Phase III top-line results indicate that the study  successfully met its primary endpoint and BEKINDA ®  24 mg was shown to be effective, safe and well tolerated in patients with acute gastroenteritis and gastritis RedHill will host a conference call and webcast to discuss the ...
    View HTML
    Toggle Summary RedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S.
    RedHill has initiated commercial activities in the U.S. with its gastrointestinal-focused sales force, promoting two gastrointestinal specialty products, Donnatal ®  and EnteraGam ® TEL-AVIV, Israel and RALEIGH, N.C. , June 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...
    View HTML
    Toggle Summary RedHill Biopharma to Present at the 2017 BIO International Convention
    TEL-AVIV, Israel , June 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, ...
    View HTML